Tag: Sarclisa
Sanofi: positive results of Sarclisa against multiple myeloma – 06/04/2024 at 09:41
(AOF) – Sanofi announces that Sarclisa (isatuximab) is capable of significantly improving the progression-free survival of patients with newly diagnosed multiple myeloma who are not eligible for transplantation. These data…
Sanofi: FDA priority approval for Sarclisa
(AOF) – Sanofi indicated that the American Food and Drug Administration (FDA) had granted priority review to the drug Sarclisa. If approved, it could be the first anti-CD38, in combination…
Sanofi-FDA grants priority review to Sarclisa – 05/27/2024 at 07:21
Sanofi SA SASY.PA: * FDA GRANTS PRIORITY REVIEW TO SARCLISA * TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA NOT ELIGIBLE FOR TRANSPLANT *FDA PRIORITY REVIEW IS DRIVEN BY POSITIVE…
Sanofi: encouraging trials for Sarclisa – 05/16/2022 at 09:53
(AOF) – Sanofi’s Sarclisa (isatuximab) combination results in unprecedented lengthening of median progression-free survival in patients with relapsed multiple myeloma treated with a proteasome inhibitor. According to the latest results…
Sanofi: positive results for Sarclisa in combination in multiple myeloma
PARIS (Agefi-Dow Jones)–The pharmaceutical company Sanofi announced on Sunday positive results for its drug Sarclisa, in combination with carfilzomib and dexamethasone, in the treatment of patients with relapsed multiple myeloma…